期 |
标题 |
文件 |
卷 2, 编号 2 (2020) |
Retraction Notice Gabidova A., Galynkin V. A unified and simplified flow diagram of the production of active pharmaceutical ingredients and the finished dosage form // Pharmacy Formulas. - 2019. - Т. 1. - №1. - C. 32-37. doi: 10.17816/phf18552 |
![PDF](/img/labels/pdf.png) (Rus)
|
Gabidova A., Galynkin V.
|
卷 2, 编号 2 (2020) |
Structural analysis of drugs assortment for etiopathogenetic therapy of children with acute viral infections |
![PDF](/img/labels/pdf.png) (Rus)
|
Narkevich I., Nemyatykh O., Timchenko V., Siukaeva D., Terninko T., Alekseeva V.
|
卷 1, 编号 1 (2019) |
Tendencies and perspectives of central alpha2-adrenomimetic application in medicobiological research |
![PDF](/img/labels/pdf.png) (Eng)
|
Vengerovich N., Ivanov I., Proshina Y.
|
卷 2, 编号 3 (2020) |
Course of intrahospital coronavirus infection (COVID-19) against the background of preventive and curative administration of peptide immunotropic drugs as part of complex therapy |
![PDF](/img/labels/pdf.png) (Rus)
|
Petlenko S., Smirnov V., Rudenko V.
|
卷 1, 编号 1 (2019) |
Pharmacists in the system of pediatric palliative care: international practice and prospects in Russia |
![PDF](/img/labels/pdf.png) (Rus)
|
Narkevich I., Nemyatykh O., Medvedeva D.
|
卷 2, 编号 2 (2020) |
Chaga and its bioactive complexes: history and perspectives |
![PDF](/img/labels/pdf.png) (Rus)
|
Zmitrovich I., Denisova N., Balandaykin M., Belova N., Bondartseva M., Perevedentseva L., Perelygin V., Yakovlev G.
|
卷 2, 编号 2 (2020) |
Experimental study of the liposomal form of fenoterol after improving the method of obtaining it |
![PDF](/img/labels/pdf.png) (Rus)
|
Ustinova T., Vengerovich N., Judin M.
|
卷 2, 编号 2 (2020) |
Electronic workflow for healthcare |
![PDF](/img/labels/pdf.png) (Rus)
|
Kiryushkin S.
|
卷 3, 编号 1 (2021) |
俄罗斯和俄罗斯联邦西北区肿瘤科客观评估系统的发展阶段 (恶性肿瘤患者发病率、死亡率、登记可靠性、年死亡率、中位生存期、观察存活率和相对存活率),第二部分。 |
![PDF](/img/labels/pdf.png) (简体中)
![PDF](/img/labels/pdf.png) (Rus)
|
Merabishvili V.M., Belyaev A.M.
|
卷 3, 编号 1 (2021) |
俄罗斯和俄罗斯联邦西北区肿瘤科活动客观评估系统的发展阶段 (恶性肿瘤患者发病率、死亡率、登记可靠性、年死亡率、中位存活期、观察存活率和相对存活率),第一部分。 |
![PDF](/img/labels/pdf.png) (简体中)
![PDF](/img/labels/pdf.png) (Rus)
|
Merabishvili V.M., Belyaev A.M.
|
201 - 210 的 210 信息 |
<< < 1 2 3 |